Ivor Caro

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 969 citations · Full text

Medicine, Melanoma, Immunology +9

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

John K. Geisse, Ivor Caro, Jane S. Lindholm et al. · Journal of the American Academy of Dermatology · 2004 · 504 citations

Medicine, Imiquimod 5, Phase Iii +8

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Paul B. Chapman, Caroline Robert, James Larkin et al. · Annals of Oncology · 2017 · 250 citations · Full text

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Craig L. Leonardi, Kim Papp, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2005 · 213 citations

Autoimmune Disease, Systemic Treatment, Clinical Trials +6

Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis

Jon M. Hanifin, Amy S. Paller, Lawrence F. Eichenfield et al. · Journal of the American Academy of Dermatology · 2005 · 136 citations

Allergy, Atopic Dermatitis, Allergy Medicine +5